Homozygous Familial Hypercholesterolemia
📧 Sign up to get email alerts when something new happens for Homozygous Familial Hypercholesterolemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-05-23FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for JUXTAPID (lomitapide) from Amryt Pharmaceuticals DAC.
-
FDA approval · 2016-03-08FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
FDA approved Amryt Pharmaceuticals DAC's supplemental application for JUXTAPID (lomitapide mesylate).
-
FDA approval · 2015-04-24FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for Juxtapid (lomitapide mesylate) submitted by Amryt Pharmaceuticals DAC.
-
FDA approval · 2015-04-23FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) submitted by Amryt Pharmaceuticals DAC, granting changes to t…
-
FDA approval · 2014-11-11FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) submitted by Amryt Pharmaceuticals DAC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-08-08FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) from Amryt Pharmaceuticals DAC.
-
FDA approval · 2014-04-23FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) filed by Amryt Pharmaceuticals DAC.
-
FDA approval · 2013-12-17FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
The FDA approved a supplemental application for JUXTAPID (lomitapide mesylate) submitted by Amryt Pharmaceuticals DAC.
-
FDA approval · 2013-08-13FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
FDA approves a supplemental application for Juxtapid (lomitapide mesylate) by Amryt Pharmaceuticals DAC, resulting in updated labeling.
-
FDA approval · 2013-04-10FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)
FDA approves a supplemental application for JUXTAPID (lomitapide) submitted by Amryt Pharmaceuticals DAC. The action represents an additiona…
-
FDA approval · 2012-12-21FDA Approved: JUXTAPID — Original Application (Amryt Pharmaceuticals DAC)
FDA approved Juxtapid (lomitapide) via an original application for homozygous familial hypercholesterolemia to reduce LDL cholesterol in aff…
-
FDA approval · 2011-12-01FDA Approved: VYTORIN — Supplemental Application (Organon LLC)
FDA approved a supplemental application for VYTORIN (ezetimibe and simvastatin) by Organon LLC, updating its labeling and indications.
-
FDA approval · 2008-06-05FDA Approved: ZETIA — Supplemental Application (Organon LLC)
The FDA approved a supplemental application for Zetia (ezetimibe) submitted by Organon LLC to update/expand aspects of its labeling.